Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105175 | 0.88 | ROCK2 (0.46) | ROCK2ROCK1GRM4CYP2D6F9 | |
| Verosudil SCHEMBL31296115 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| Hydrochloric Acid SCHEMBL1096786 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1GRM4F9 | |
| Hydrochloric Acid SCHEMBL1096782 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1GRM4F9 | |
| Verosudil SCHEMBL30518358 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| Verosudil SCHEMBL1097102 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| Verosudil SCHEMBL30518344 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| Verosudil SCHEMBL16036842 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| Verosudil SCHEMBL1097105 | 0.86 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 | |
| SCHEMBL14642427 | 0.85 | ROCK2 (0.45) | ROCK2ROCK1GRM4F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236477-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2021-08-05 | — | — | US | disclosed |
| US-9415043-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140275161-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236477-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885PSEN1 3354/4885 |
| US-20140275161-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885PSEN1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.